CASP3 and neoplasm: Treatment efficacy was evaluated by assessing the changes in tumor cell viability (CCK8), morphology (H&E), proliferation (Ki-67) and induction of apoptosis (cleaved caspase-3) after treating tumor explants with cetuximab.